Author:
Song Isabel,Thompson Elizabeth W.,Verma Anurag,MacLean Matthew T.,Duda Jeffrey,Elahi Ameena,Tran Richard,Raghupathy Pavan,Swago Sophia,Hazim Mohamad,Bhattaru Abhijit,Schneider Carolin,Vujkovic Marijana,Torigian Drew A.,Kahn Charles E.,Gee James C.,Borthakur Arijitt,Kripke Colleen M.,Carson Christopher C.,Carr Rotonya,Jehangir Qasim,Ko Yi-An,Litt Harold,Rosen Mark,Mankoff David A.,Schnall Mitchell D.,Shou Haochang,Chirinos Julio,Damrauer Scott M.,Serper Marina,Chen Jinbo,Rader Daniel J., ,Ritchie Marylyn D.,Weaver JoEllen,Naseer Nawar,Poindexter Afiya,Hu-Sain Khadijah,Livingstone Meghan,Vadivieso Fred,DerOhannessian Stephanie,Tran Teo,Stephanowski Julia,Zielinski Monica,Haubein Ned,Dunn Joseph,Verma Anurag,Kripke Colleen M.,Risman Marjorie,Judy Renae,Verma Shefali S.,Bradford Yuki,Dudek Scott,Drivas Theodore,Witschey Walter R. T.,Sagreiya Hersh
Abstract
AbstractThe objective of this study is to define CT imaging derived phenotypes for patients with hepatic steatosis, a common metabolic liver condition, and determine its association with patient data from a medical biobank. There is a need to further characterize hepatic steatosis in lean patients, as its epidemiology may differ from that in overweight patients. A deep learning method determined the spleen-hepatic attenuation difference (SHAD) in Hounsfield Units (HU) on abdominal CT scans as a quantitative measure of hepatic steatosis. The patient cohort was stratified by BMI with a threshold of 25 kg/m2 and hepatic steatosis with threshold SHAD ≥ − 1 HU or liver mean attenuation ≤ 40 HU. Patient characteristics, diagnoses, and laboratory results representing metabolism and liver function were investigated. A phenome-wide association study (PheWAS) was performed for the statistical interaction between SHAD and the binary characteristic LEAN. The cohort contained 8914 patients—lean patients with (N = 278, 3.1%) and without (N = 1867, 20.9%) steatosis, and overweight patients with (N = 1863, 20.9%) and without (N = 4906, 55.0%) steatosis. Among all lean patients, those with steatosis had increased rates of cardiovascular disease (41.7 vs 27.8%), hypertension (86.7 vs 49.8%), and type 2 diabetes mellitus (29.1 vs 15.7%) (all p < 0.0001). Ten phenotypes were significant in the PheWAS, including chronic kidney disease, renal failure, and cardiovascular disease. Hepatic steatosis was found to be associated with cardiovascular, kidney, and metabolic conditions, separate from overweight BMI.
Funder
Penn Undergraduate Research Mentoring Program
Sarnoff Cardiovascular Research Foundation
National Institutes of Health
Radiological Society of North America
Publisher
Springer Science and Business Media LLC